G
228760
vs
K
KOSPI 200
Over the past 12 months, Genomictree Inc has underperformed KOSPI 200, delivering a return of +17% compared to the KOSPI 200's +114% growth.
Stocks Performance
228760 vs KOSPI 200
Performance Gap
228760 vs KOSPI 200
Performance By Year
228760 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genomictree Inc
Glance View
Genomictree, Inc. engages in the development and supply of diagnostic products for cancer screening and prognosis. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-07-19. The firm is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.
